IL319205A - Antibody conjugates against TISSUE FACTOR and drug and their uses - Google Patents

Antibody conjugates against TISSUE FACTOR and drug and their uses

Info

Publication number
IL319205A
IL319205A IL319205A IL31920525A IL319205A IL 319205 A IL319205 A IL 319205A IL 319205 A IL319205 A IL 319205A IL 31920525 A IL31920525 A IL 31920525A IL 319205 A IL319205 A IL 319205A
Authority
IL
Israel
Prior art keywords
tissue factor
drug conjugates
factor antibody
antibody
conjugates
Prior art date
Application number
IL319205A
Other languages
English (en)
Hebrew (he)
Inventor
Robyn M Barfield
Maxine Bauzon
Penelope M Drake
Seema Kantak
Brian Alan Mendelsohn
Tiffany Unsulangi
Original Assignee
Exelixis Inc
Robyn M Barfield
Maxine Bauzon
Penelope M Drake
Seema Kantak
Brian Alan Mendelsohn
Tiffany Unsulangi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc, Robyn M Barfield, Maxine Bauzon, Penelope M Drake, Seema Kantak, Brian Alan Mendelsohn, Tiffany Unsulangi filed Critical Exelixis Inc
Publication of IL319205A publication Critical patent/IL319205A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL319205A 2022-09-07 2023-09-06 Antibody conjugates against TISSUE FACTOR and drug and their uses IL319205A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263404447P 2022-09-07 2022-09-07
US202363498233P 2023-04-25 2023-04-25
PCT/US2023/073516 WO2024054821A2 (fr) 2022-09-07 2023-09-06 Conjugués anticorps-médicament de facteur tissulaire et leurs utilisations

Publications (1)

Publication Number Publication Date
IL319205A true IL319205A (en) 2025-04-01

Family

ID=90191921

Family Applications (1)

Application Number Title Priority Date Filing Date
IL319205A IL319205A (en) 2022-09-07 2023-09-06 Antibody conjugates against TISSUE FACTOR and drug and their uses

Country Status (15)

Country Link
EP (1) EP4583922A2 (fr)
JP (1) JP2025530129A (fr)
KR (1) KR20250060248A (fr)
CN (1) CN120129535A (fr)
AU (1) AU2023338206A1 (fr)
CA (1) CA3265517A1 (fr)
CL (1) CL2025000595A1 (fr)
CO (1) CO2025003047A2 (fr)
CR (1) CR20250074A (fr)
DO (1) DOP2025000050A (fr)
IL (1) IL319205A (fr)
MX (1) MX2025002614A (fr)
PE (1) PE20251256A1 (fr)
TW (1) TW202423991A (fr)
WO (1) WO2024054821A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025081117A2 (fr) * 2023-10-13 2025-04-17 Sutro Biopharma, Inc. Anticorps anti-facteur tissulaire et conjugués d'anticorps, compositions comprenant des anticorps anti-facteur tissulaire ou des conjugués d'anticorps, et méthodes de fabrication et d'utilisation d'anticorps anti-facteur tissulaire et de conjugués d'anticorps

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220153871A1 (en) * 2018-01-04 2022-05-19 Iconic Therapeutics, Inc. Anti-Tissue Factor Antibodies, Antibody-Drug Conjugates, and Related Methods
CA3198788A1 (fr) * 2021-01-15 2022-07-21 R.P. Scherer Technologies, Llc Conjugues anticorps-medicament de camptothecine et leurs methodes d?utilisation
JP2025516569A (ja) * 2022-05-13 2025-05-30 エグゼリクシス， インコーポレイテッド ５ｔ４抗体薬物複合体及びその使用

Also Published As

Publication number Publication date
CN120129535A (zh) 2025-06-10
CR20250074A (es) 2025-04-10
WO2024054821A2 (fr) 2024-03-14
JP2025530129A (ja) 2025-09-11
KR20250060248A (ko) 2025-05-07
CO2025003047A2 (es) 2025-03-27
CL2025000595A1 (es) 2025-05-02
TW202423991A (zh) 2024-06-16
CA3265517A1 (fr) 2024-03-14
WO2024054821A3 (fr) 2024-04-11
AU2023338206A1 (en) 2025-03-06
PE20251256A1 (es) 2025-05-06
MX2025002614A (es) 2025-04-02
EP4583922A2 (fr) 2025-07-16
DOP2025000050A (es) 2025-04-08

Similar Documents

Publication Publication Date Title
IL308246A (en) Exataxane derivatives and antibody-drug conjugates thereof
CA3256212A1 (fr) Conjugués anticorps-médicament, procédés de préparation et utilisation associées
IL304168A (en) Antibody-drug conjugates target b7h4 and methods of using them
IL302122A (en) Antibody-drug conjugation and its application
IL314828A (en) Antibody-drug conjugates and their uses
AU2022205057A9 (en) B7h4-targeted antibody-drug conjugates and methods of use thereof
AU2021359562A9 (en) Antibody-drug conjugate and application thereof
IL317101A (en) Antibody-drug conjugates of anticancer compounds and methods of using them
IL320634A (en) EXATECAN derivatives and antibody-drug conjugates
IL299334A (en) Antibody-antidrug-tissue factor conjugates and their use in cancer treatment
IL299184A (en) Anti-folic acid drugs and antibody-conjugated drugs
IL300176A (en) Anti-CD228 antibodies and antibody-drug conjugates
IL307282A (en) Antidote conjugates against HER2 and their applications
IL318188A (en) Antibody-drug conjugates
IL319484A (en) Antibody compositions for drugs targeting NAPI2B and methods of use
IL320894A (en) ceacam5 antibody conjugates – drug and methods of using them
IL324678A (en) Drug binders and drug conjugates
IL316790A (en) Antibody conjugates against 5T4 with a drug and their uses
IL319205A (en) Antibody conjugates against TISSUE FACTOR and drug and their uses
IL316020A (en) Conjugations of antidote drugs based on arbolin and methods of use
IL324461A (en) Anti-PDL1 antibody-drug conjugate and use thereof
IL325400A (en) Anti-human CACNG1 antibody-drug conjugates and their uses
HK40121438A (en) Antibody-drug conjugate and use thereof
CA3289393A1 (fr) Conjugué anticorps-médicament anti-cdh6 et son utilisation
CA3278529A1 (fr) Conjugué anticorps-médicament anti-bdca2 et son utilisation